Promoted Content

Promoted Content

All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

CPhI India 2021

Participation Not Confirmed

Update your events

Novartis' Phase IV Study Showed Superior Tolerability and Efficacy of Aimovig® Compared to Topiramate in Migraine Prevention

Contact the Supplier

Lead Product(s): Erenumab

Therapeutic Area: Neurology Product Name: Aimovig

Highest Development Status: Phase IV Product Type: Large molecule

Partner/Sponsor/Collaborator: Amgen Inc

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 02, 2020

Details:

The first randomized, double blind, head-to-head study of Aimovig® (erenumab) against topiramate in patients with episodic and chronic migraine (HER-MES) achieved superiority in its primary and secondary endpoints.